Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418270 | PMC |
| http://dx.doi.org/10.2340/actadv.v104.40800 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.
Acta Derm Venereol
September 2024
Section of Dermatology - Department of Health Sciences, University of Genoa, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy.
Tralokinumab as an effective alternative after dupilumab treatment failure in moderate-to-severe atopic dermatitis: A real-world study.
J Am Acad Dermatol
December 2024
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:
[Severe atopic dermatitis in childhood in the era of personalized medicine].
Andes Pediatr
June 2024
Facultad de Medicina, Universidad del Desarrollo, Santiago, Chile.
Atopic dermatitis (AD) is a chronic, non-infectious inflammatory dermatosis, with increasing prevalence in recent decades. Due to its chronic and recurrent nature, it diminishes the quality of life of patients and their families. In recent years, advances in the understanding of AD's pathophysiology have driven the development of targeted therapies such as monoclonal antibodies (mAbs) and Janus kinase inhibitors (JAKis) which modulate the immune system through specific signaling pathways, providing effective alternatives to traditional systemic immunosuppressive agents.
View Article and Find Full Text PDFAbrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Health Technol Assess
January 2024
Associate Professor in Inflammatory Skin Diseases, University of Leeds, Leeds, UK.
Article Synopsis
- Atopic dermatitis is a chronic skin condition, commonly seen in children, characterized by dry, itchy, and inflamed skin, often appearing before age 5 but can develop at any time.
- The study evaluates the clinical effectiveness and cost-effectiveness of three newer treatments—abrocitinib, tralokinumab, and upadacitinib—compared to traditional treatments like ciclosporin A and dupilumab for moderate-to-severe atopic dermatitis.
- A systematic review and network meta-analysis were conducted to analyze various treatment pathways and their outcomes, ultimately informing a new economic model for the NHS in England regarding treatment costs and effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!